פוסט זה זמין גם ב:
עברית
Contributor: Ricky Dhaliwal, MD
Educational Pearls:
- CRASH 3 Trial looked at over 12,000 patients with traumatic intracranial bleeds, randomizing patients to a therapy with TXA or standard of care without TXA
- Dosing was 1 gram over 10 min for loading dose and then an infusion of 1 gram over 8 hours
- Found Improvement in survival and neurologic outcomes when patient received TXA within 3 hours
References
CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial [published correction appears in Lancet. 2019 Nov 9;394(10210):1712]. Lancet. 2019;394(10210):1713-1723. doi:10.1016/S0140-6736(19)32233-0
